{"id":"dp","safety":{"commonSideEffects":[{"rate":"null","effect":"Allergic reactions"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea and vomiting"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":{"setId":"5e39f4e6-939f-4b71-9cc5-6d4b8711ea32","title":"DPT-TOX (DROSERA, ECHINACEA, HYPERICUM, KALI MUR, MEZEREUM, SILICEA, THUJA) SOLUTION/ DROPS [NUTRITION CENTER INC DBA NUTRI-WEST DBA MICRO-WEST]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DP works by inhibiting the synthesis of bacterial cell walls, ultimately leading to the death of the bacteria. This is achieved through the inhibition of the enzyme transpeptidase, which is essential for the cross-linking of peptidoglycan in the bacterial cell wall.","oneSentence":"DP is a medication used to treat certain types of infections caused by bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:59.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of infections caused by susceptible bacteria, including pneumonia, skin and soft tissue infections, and urinary tract infections"}]},"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT03798678","phase":"PHASE1","title":"CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-08","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":36},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT04847453","phase":"PHASE1","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-03","conditions":"Recurrent AL Amyloidosis, Refractory AL Amyloidosis","enrollment":24},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT06871150","phase":"NA","title":"Three Different GHDT ( Goal Hemodynamic Directed Therapy) Strategies for Intraoperative Fluid Management Optimization During Major Abdominal Surgery: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"ASST Sette Laghi","startDate":"2026-03-02","conditions":"Hemodynamic","enrollment":150},{"nctId":"NCT07161466","phase":"NA","title":"Effects of Positive End-Expiratory Pressure Levels on Lung Recruitment Duration and Hemodynamics After Alveolar Recruitment Maneuver: A Randomized Clinical Trial","status":"COMPLETED","sponsor":"Northern Jiangsu People's Hospital","startDate":"2025-08-30","conditions":"Dynamic Lung Compliance, Alveolar Recruitment Maneuver","enrollment":101},{"nctId":"NCT06513546","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients","status":"NOT_YET_RECRUITING","sponsor":"PLL TX AUSTRALIA PTY LTD","startDate":"2026-04-08","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":153},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT07476183","phase":"PHASE1","title":"Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia","status":"NOT_YET_RECRUITING","sponsor":"Apriligen, Inc.","startDate":"2026-03","conditions":"RPS19 Deficient Diamond-Blackfan Anemia","enrollment":4},{"nctId":"NCT07477951","phase":"NA","title":"The Impact of Automatic Lung Recruitment Postoperative Pulmonary Complications","status":"NOT_YET_RECRUITING","sponsor":"Yongtao Sun","startDate":"2026-04-01","conditions":"Acute Lung Injury","enrollment":58},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma","enrollment":53},{"nctId":"NCT07226791","phase":"PHASE2","title":"Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-02-04","conditions":"Ventral Hernia","enrollment":200},{"nctId":"NCT06186401","phase":"PHASE1","title":"Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells","status":"RECRUITING","sponsor":"Hideho Okada, MD, PhD","startDate":"2024-04-30","conditions":"EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma","enrollment":20},{"nctId":"NCT04883242","phase":"PHASE2","title":"Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT07457164","phase":"PHASE2","title":"A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Antev Ltd.","startDate":"2026-07","conditions":"Advanced Prostate Cancer, GnRH Antagonist","enrollment":40},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT03505983","phase":"NA","title":"Criteria for Advanced Prosthetic Foot Prescription","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA New York Harbor Healthcare System","startDate":"2018-03-07","conditions":"Prosthesis User, Amputation; Traumatic, Limb, Lower","enrollment":91},{"nctId":"NCT05660408","phase":"PHASE1, PHASE2","title":"RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-03-12","conditions":"Recurrent Pulmonary Osteosarcoma, Recurrent High-grade Glioma","enrollment":36},{"nctId":"NCT06203912","phase":"PHASE1","title":"Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elvira Umyarova","startDate":"2024-03-05","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":3},{"nctId":"NCT03260491","phase":"PHASE1","title":"U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2017-10-30","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":312},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT07110428","phase":"NA","title":"Supraglottic Jet Oxygenation Ventilation During Hysteroscopic Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-07-03","conditions":"Hysteroscopic Surgery","enrollment":100},{"nctId":"NCT03326336","phase":"PHASE1, PHASE2","title":"Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa","status":"ACTIVE_NOT_RECRUITING","sponsor":"GenSight Biologics","startDate":"2018-09-26","conditions":"Non-syndromic Retinitis Pigmentosa","enrollment":10},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT04764942","phase":"PHASE1, PHASE2","title":"Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-05-06","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":39},{"nctId":"NCT07431242","phase":"","title":"Mechanical Power and Driving Pressure Exposure in Laparoscopic Surgery","status":"NOT_YET_RECRUITING","sponsor":"Istinye University","startDate":"2026-02-25","conditions":"Postoperative Pulmonary Complications","enrollment":90},{"nctId":"NCT07429162","phase":"PHASE1","title":"Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection","status":"NOT_YET_RECRUITING","sponsor":"Alberta Health services","startDate":"2026-07-02","conditions":"Mycobacterium Abscessus Infection, Bacteriophage Therapy, Pulmonary Disease","enrollment":1},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":21},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT04754945","phase":"PHASE1","title":"Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-04-28","conditions":"AL Amyloidosis","enrollment":11},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT07403643","phase":"PHASE4","title":"Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria","status":"NOT_YET_RECRUITING","sponsor":"Curtin University","startDate":"2026-04","conditions":"Uncomplicated Malaria","enrollment":60},{"nctId":"NCT07406308","phase":"EARLY_PHASE1","title":"A Comparative Analysis of Mid- to Long-Term Outcomes: Paclitaxel-Coated Balloon With Debulking Versus Paclitaxel-Coated Balloon Alone in the Treatment of Chronic Femoropopliteal Artery Occlusions","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-04-20","conditions":"Femoropopliteal Artery Occlusion","enrollment":408},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT06132685","phase":"PHASE2","title":"Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-09","conditions":"Low Grade Glioma, Malignant Brain Glioma, Malignant Brain Neoplasm","enrollment":200},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT03031730","phase":"PHASE1","title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-14","conditions":"Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":35},{"nctId":"NCT06768944","phase":"PHASE2","title":"Subjective Experience Following Psilocybin","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2026-04","conditions":"Investigating the Importance of the Subjective Psychedelic Experience","enrollment":128},{"nctId":"NCT05497804","phase":"PHASE2","title":"Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-09-22","conditions":"ISS Stage III Plasma Cell Myeloma, Multiple Myeloma","enrollment":17},{"nctId":"NCT05981209","phase":"PHASE1","title":"Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies","status":"RECRUITING","sponsor":"Abdullah Khan","startDate":"2023-12-21","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":27},{"nctId":"NCT06538636","phase":"NA","title":"Prediction Augmented Screening Initiative","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Lung Cancer, Lung Cancer Screening","enrollment":23520},{"nctId":"NCT07076290","phase":"PHASE1","title":"A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD","status":"NOT_YET_RECRUITING","sponsor":"Rise Therapeutics LLC","startDate":"2026-09-01","conditions":"COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbation, COPD Exacerbation Acute","enrollment":27},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":"Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":13},{"nctId":"NCT07366411","phase":"PHASE2","title":"taVNS on Functional Mobility in People With DP","status":"NOT_YET_RECRUITING","sponsor":"Universidade Federal de Pernambuco","startDate":"2026-02-15","conditions":"PARKINSON DISEASE (Disorder)","enrollment":30},{"nctId":"NCT04180059","phase":"PHASE1","title":"Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2020-02-09","conditions":"Haematologic Disease","enrollment":6},{"nctId":"NCT06616584","phase":"PHASE2, PHASE3","title":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-05-22","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":378},{"nctId":"NCT07246525","phase":"PHASE4","title":"Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-05-01","conditions":"Malaria","enrollment":4800},{"nctId":"NCT05455320","phase":"PHASE3","title":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-13","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":864},{"nctId":"NCT06430359","phase":"","title":"Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-01-10","conditions":"Wilson Disease","enrollment":30},{"nctId":"NCT06404749","phase":"NA","title":"Fungal Fiber for Gut Health","status":"TERMINATED","sponsor":"Future Biome SA","startDate":"2024-05-03","conditions":"Mild Gastrointestinal Symptoms in Healthy Adults, Low-grade Chronic Inflammation, Stress","enrollment":8},{"nctId":"NCT03808610","phase":"PHASE1, PHASE2","title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-03","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT05902520","phase":"PHASE1","title":"Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgonOx, Inc.","startDate":"2023-06-19","conditions":"HNSCC, Melanoma, Gynecologic Cancer","enrollment":18},{"nctId":"NCT07322068","phase":"PHASE4","title":"Perennial Malaria Chemoprevention in the Malaria Vaccine Era","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-09","conditions":"Malaria, Falciparum","enrollment":1290},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":160},{"nctId":"NCT06274333","phase":"PHASE3","title":"Adding Dexmedetomidine or Tramadol to Paracetamol- An Effort to Attenuate Catheter Related Bladder Discomfort","status":"RECRUITING","sponsor":"Al-Azhar University","startDate":"2024-02-28","conditions":"Percutaneous Nephrolithotripsy (PCNL)","enrollment":60},{"nctId":"NCT06109441","phase":"PHASE2","title":"Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AltruBio Inc.","startDate":"2023-12-04","conditions":"Ulcerative Colitis","enrollment":50},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT03583255","phase":"PHASE2","title":"Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-06-29","conditions":"Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm","enrollment":99},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT07169643","phase":"PHASE3","title":"Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2025-11-25","conditions":"Liver Transplant; Complications","enrollment":140},{"nctId":"NCT07285421","phase":"NA","title":"Renal and Vascular Phenotypic Characterization of Patients With Enamel Renal Syndrome Due to a Pathogenic Variant of the FAM20A Gene and Pathophysiological Study of Ectopic Calcifications","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-01","conditions":"Enamel Renal Syndrome","enrollment":30},{"nctId":"NCT06245356","phase":"PHASE2","title":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-03-21","conditions":"Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency","enrollment":73},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":"Recurrent B Acute Lymphoblastic Leukemia","enrollment":669},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":"Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","enrollment":847},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":488},{"nctId":"NCT00098475","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11-03","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":452},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT02427620","phase":"PHASE2","title":"Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-03","conditions":"Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma","enrollment":131},{"nctId":"NCT06962319","phase":"PHASE3","title":"Safety of Antimalarials in the FIRst trimEster","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-30","conditions":"Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)","enrollment":1510},{"nctId":"NCT06083688","phase":"PHASE4","title":"Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi","status":"ACTIVE_NOT_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2024-10-14","conditions":"Malaria,Falciparum, Anemia in Children","enrollment":1000},{"nctId":"NCT05514990","phase":"PHASE1, PHASE2","title":"Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2022-10-07","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":10},{"nctId":"NCT03656718","phase":"PHASE1, PHASE2","title":"A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-29","conditions":"Neoplasms by Site","enrollment":139},{"nctId":"NCT03367156","phase":"PHASE2","title":"Dexamethasone in Controlling Dyspnea in Patients With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-04","conditions":"Dyspnea, Malignant Neoplasm","enrollment":135},{"nctId":"NCT04336189","phase":"PHASE3","title":"Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda","status":"COMPLETED","sponsor":"Grant Dorsey, M.D, Ph.D.","startDate":"2020-12-28","conditions":"Malaria","enrollment":2757},{"nctId":"NCT02877303","phase":"PHASE2","title":"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-01","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT03132454","phase":"PHASE1","title":"Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-25","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":32},{"nctId":"NCT05392946","phase":"PHASE1, PHASE2","title":"Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-08-11","conditions":"Plasma Cell Myeloma","enrollment":49},{"nctId":"NCT03763162","phase":"PHASE2","title":"Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-17","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":40},{"nctId":"NCT06785415","phase":"PHASE1, PHASE2","title":"Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-03-18","conditions":"Recurrent Multiple Myeloma","enrollment":37},{"nctId":"NCT06905509","phase":"PHASE2","title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","enrollment":25},{"nctId":"NCT05350501","phase":"PHASE2","title":"EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer","status":"TERMINATED","sponsor":"Enterome","startDate":"2023-03-01","conditions":"Colorectal Cancer","enrollment":1},{"nctId":"NCT00595491","phase":"PHASE1","title":"Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation","status":"RECRUITING","sponsor":"Benjamin Medoff","startDate":"2008-01","conditions":"Asthma","enrollment":313},{"nctId":"NCT05961592","phase":"PHASE1","title":"R-2487 in Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Rise Therapeutics LLC","startDate":"2023-10-19","conditions":"Arthritis, Rheumatoid","enrollment":73},{"nctId":"NCT04726852","phase":"","title":"Arterial Pressure vs. TE Echo dp/dt","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2021-02-02","conditions":"Myocardial Contraction","enrollment":43},{"nctId":"NCT04776395","phase":"PHASE2","title":"Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-11-02","conditions":"Smoldering Plasma Cell Myeloma","enrollment":68},{"nctId":"NCT06022939","phase":"PHASE3","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-07-01","conditions":"AL Amyloidosis","enrollment":338},{"nctId":"NCT04546399","phase":"PHASE2","title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":"Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia","enrollment":461},{"nctId":"NCT03440801","phase":"NA","title":"A Randomized Comparison of Long-Term Healing Between Biodegradable- Versus Durable-Polymer Everolimus Eluting Stents in STEMI","status":"COMPLETED","sponsor":"Tokorozawa Heart Center","startDate":"2017-07-03","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":240},{"nctId":"NCT05592002","phase":"NA","title":"Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nyxoah S.A.","startDate":"2022-12-28","conditions":"Sleep Apnea, Obstructive","enrollment":124},{"nctId":"NCT01415882","phase":"PHASE2","title":"Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01-31","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":165},{"nctId":"NCT06297213","phase":"PHASE1","title":"R-2487 in Patients With Sjogren's Syndrome (SS)","status":"NOT_YET_RECRUITING","sponsor":"Rise Therapeutics LLC","startDate":"2026-06-01","conditions":"Sjogren's Syndrome, Sjögren, Sjögren Syndrome, Unspecified","enrollment":36},{"nctId":"NCT06873659","phase":"PHASE1","title":"SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Qurgen Inc.","startDate":"2025-02-26","conditions":"Solid Tumor, Gastric Cancer, Liver Cancer","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33944,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DuoCotecxin, Holley Pharm"],"phase":"marketed","status":"active","brandName":"DP","genericName":"DP","companyName":"Medecins Sans Frontieres, Netherlands","companyId":"medecins-sans-frontieres-netherlands","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DP is a medication used to treat certain types of infections caused by bacteria. Used for Treatment of infections caused by susceptible bacteria, including pneumonia, skin and soft tissue infections, and urinary tract infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}